<DOC>
	<DOC>NCT01025843</DOC>
	<brief_summary>This is a two part introductory clinical trial with MK-5478. Part I will evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of MK-5478 in young, healthy males. Part II will evaluate the safety, tolerability and pharmacodynamic effects of MK-5478 in participants with hypertension. The primary hypothesis is that single oral doses of MK-5478 are sufficiently safe and well tolerated.</brief_summary>
	<brief_title>Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Part I: Is a male between 18 to 50 years of age Is in good health Is a nonsmoker Part II: Is male of nonchild bearing potential between 18 and 50 years of age Has hypertension (high blood pressure) Part I and Part II: Has a history of stroke, seizures or major neurological disorder Has a history of cancer Has a history of any cardiovascular disease Is unable to refrain from the use of any prescription or nonprescription drugs Consumes excessive amounts of alcohol or caffeine Has had major surgery, donated blood or participated in another investigational study in the past 4 weeks</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>